Indication
In combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired human immunodeficiency-1 (HIV-1) infection in high-risk adults and adolescents, weighing at least 35 kg.
Medicine details
- Medicine name:
- cabotegravir (Apretude)
- SMC ID:
- SMC2718
- Pharmaceutical company
- ViiV Healthcare
- BNF chapter
- Infections
- Submission type
- Full
- Publication due date:
- 10 February 2025
- SMC meeting date:
- 07 January 2025
- Patient group submission deadline:
- 04 November 2024